Clínic Barcelona

First molecular test that enables fine-tuned prognosis and prediction in advanced breast cancer

Published today in JAMA Oncology, Principal Investigator of Vall d´Hebron Institute of Oncology´s (VHIO) Translational Genomics Group, and now  Team Leader of translational genomics and targeted therapeutics in solid tumors at the August Pi I Sunyer Biomedical Research Institute (IDIBAPS), and Head of Medical Oncology at the Hospital Clínic in Barcelona, Aleix Prat, has led a study showing the intrinsic subtyping of breast cancer by means of a genomic test as the most important prognostic factor in advanced or metastatic hormone-sensitive breast cancer. Findings show that the genomic classification of tumors -- the molecular subtyping of primary tumors, can predict the evolution of patients from the onset of metastasis and that this cancer intrinsic classification can better guide treatment decisions in the first-line metastatic setting.